The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

Oxford University Press (OUP) - Tập 18 Số 1 - Trang 9-17 - 2003
Eric Orwoll1, W. H. Scheele2, St Paul2, S. Adámi3, Unni Syversen4, Adolfo Díez‐Pérez5, J-M. Kaufman6, AD Clancy2, Gregory A. Gaich2
1Oregon Health and Sciences University and Veterans Affairs Medical Center, Portland, Oregon, USA
2Eli Lilly and Company, Indianapolis, Indiana, USA.
3University of Verona, Valeggio sul Minicio (VR), Italy
4University Hospital, Trondheim, Norway
5Hospital del Mar, Barcelona, Spain
6Ghent University Hospital, Ghent, Belgium

Tóm tắt

Abstract Teriparatide [rhPTH(1–34)] increases bone mineral density and reduces the risk of vertebral fracture in women. We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 μg, or teriparatide 40 μg. All subjects also received supplemental calcium and vitamin D. The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies. Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity. Spine bone mineral density was greater than in placebo subjects after 3 months of teriparatide therapy, and by the end of therapy it was increased by 5.9% (20 μg) and 9.0% (40 μg) above baseline (p < 0.001 vs. placebo for both comparisons). Femoral neck bone mineral density increased 1.5% (20 μg; p = 0.029) and 2.9% (40 μg; p < 0.001), and whole body bone mineral content increased 0.6% (20 μg; p = 0.021) and 0.9% (40 μg; p = 0.005) above baseline in the teriparatide subjects. There was no change in radial bone mineral density in the teriparatide groups. Bone mineral density responses to teriparatide were similar regardless of gonadal status, age, baseline bone mineral density, body mass index, smoking, or alcohol intake. Subjects experienced expected changes in mineral metabolism. Adverse events were similar in the placebo and 20-μg groups, but more frequent in the 40-μg group. This study shows that teriparatide treatment results in an increase in bone mineral density and is a potentially useful therapy for osteoporosis in men.

Từ khóa


Tài liệu tham khảo

Orwoll, 1998, Osteoporosis in men, Endocrinol Metab Clin North Am, 27, 349, 10.1016/S0889-8529(05)70009-8

Kaufman, 2000, Background for studies on the treatment of male osteoporosis: state of the art, Ann Rheum Dis, 59, 765, 10.1136/ard.59.10.765

Gullberg, 1997, World-wide projections for hip fracture, Osteoporos Int, 7, 407, 10.1007/PL00004148

Cooper, 1992, Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985–1989, J Bone Miner Res, 7, 221, 10.1002/jbmr.5650070214

O'Neill, 1996, The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study, J Bone Miner Res, 11, 1010, 10.1002/jbmr.5650110719

Burger, 1997, Vertebral deformities and functional impairment in men and women, J Bone Miner Res, 12, 152, 10.1359/jbmr.1997.12.1.152

Melton, 1999, Vertebral fractures predict subsequent fractures, Osteoporos Int, 10, 214, 10.1007/s001980050218

Orwoll, 1995, Osteoporosis in men, Endocrinol Rev, 16, 87, 10.1210/edrv-16-1-87

Orwoll, 2000, Alendronate for the treatment of osteoporosis in men, N Engl J Med, 343, 604, 10.1056/NEJM200008313430902

Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904

Slovik, 1986, Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin D, J Bone Miner Res, 1, 377, 10.1002/jbmr.5650010411

Kurland, 2000, Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers, J Clin Endocrinol Metab, 85, 3069

Vahle, 2002, Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1–34) for 2 years and relevance to human safety, Toxicol Pathol, 30, 312, 10.1080/01926230252929882

Satterwhite, 2001, Men and postmenopausal women with osteoporosis have similar lumbar spine bone mineral density responses to recombinant human parathyroid hormone (1–34) despite pharmacokinetic and biochemical marker differences, Arthritis Rheum, 44, S255

Rosen, 2001, Clinical review 123: Anabolic therapy for osteoporosis, J Clin Endocrinol Metab, 86, 957, 10.1210/jcem.86.3.7366

Delmas, 2000, Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs, Osteoporos Int, 11, S66, 10.1007/s001980070007

Cosman, 1998, Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone, J Clin Endocrinol Metab, 83, 788

Fukayama, 1989, Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein, Endocrinology, 125, 1789, 10.1210/endo-125-4-1789

Fukayama, 1989, Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein, Endocrinology, 124, 397, 10.1210/endo-124-1-397

Mosekilde, 1994, The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1–38), and combination therapy, assessed in aged ovariectomized rats, Endocrinology, 134, 2126, 10.1210/endo.134.5.8156913

Khosla, 1998, Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen, J Clin Endocrinol Metab, 83, 2266

Tashjian, 2002, Clinical safety of recombinant human parathyroid hormone (1–34) in the treatment of osteoporosis in postmenopausal women and men, J Bone Miner Res, 17, 1151, 10.1359/jbmr.2002.17.7.1151

Ste-Marie, 2001, Bone mineral density changes during an 18 month observational period following discontinuation of recombinant human parathyroid hormone (1–34) treatment of postmenopausal women receiving hormone replacement therapy, Arthritis Rheum, 44, S257

Kulkarni, 2001, Lumbar spine bone mineral density response rates in a study of recombinant human parathyroid hormone (1–34) compared to alendronate sodium in postmenopausal women with osteoporosis, Arthritis Rheum, 44, S379

Orwoll, 2001, Brief therapy with recombinant human parathyroid hormone (1–34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteoporosis, J Bone Miner Res, 16, S1;S221

Lindsay, 2001, Incident vertebral fractures during an 18 month observation period following discontinuation of LY333334 [recombinant human parathyroid hormone (1–34), rhPTH (1–34)] use in postmenopausal women with osteoporosis, J Bone Miner Res, 16, S1;S163

Palmer, 1988, Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study, Am J Epidemiol, 127, 1031, 10.1093/oxfordjournals.aje.a114879

Wermers, 1998, Survival after the diagnosis of hyperparathyroidism: A population-based study, Am J Med, 104, 115, 10.1016/S0002-9343(97)00270-2

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Tập 18 Số 1

9-17

Thông tin tác giả